Bioanalytical method to detect midazolam in plasma.

Area of Science:

• Analytical Chemistry
• Pharmacology

Background:

• Midazolam (MDZ) is crucial for palliative sedation and anesthesia induction due to its rapid action.
• Current methods for monitoring patient sedation levels with MDZ lack accuracy.
• Accurate MDZ quantification in plasma is needed for improved clinical management.

Purpose of the Study:

• To develop and validate a sensitive bioanalytical method for detecting midazolam in human plasma.
• To establish a reliable tool for monitoring midazolam levels and patient sedation.

Main Methods:

• Developed a method using high-performance liquid chromatography (HPLC) with a photodiode array detector (PDA).
• Employed solid-phase extraction (SPE) for sample preparation.
• Validated the method for linearity, precision, accuracy, specificity, and sensitivity.

Main Results:

• The SPE method achieved a mean recovery of 101.03%.
• The method demonstrated linearity from 1.0-50.0 μg/mL with limits of detection (LD) and quantification (LQ) of 0.43 and 1.43 μg/mL, respectively.
• The method showed specificity for MDZ, with no interference from plasma anticoagulants.

Conclusions:

• The validated HPLC-PDA and SPE bioanalytical method is accurate, precise, and sensitive for midazolam detection in human plasma.
• This method provides a reliable approach for monitoring midazolam levels, potentially enhancing sedation management.
• The validated method supports future clinical applications in patient sedation monitoring.